Ilant Health, a value-based obesity treatment company, has raised $15 million in a Series A led by Cornucopian Capital, with participation from naturalX, Peakbridge, Semcap AI, Evidenced, Operator Partners, and existing investors Celtic, LifeX, and AlphaLab. Total funding to date is over $22 million.
Founded by Elina Onitskansky, Ilant works with employers and health plans to deliver clinician-led care that precision-matches treatment to individual needs based on clinical, behavioral, and personal data – continuously adapting as each person responds. Treatment spans behavioral therapy, medication (both GLP-1 and non-GLP-1), surgical options, and support for nutrition, physical activity, and stress.
Early results show members achieving 15% average weight loss – nearly three times the 5.8% reported in real-world settings – alongside an average of two additional mentally healthy days per month.
“Employers and health plans are facing a real dilemma right now – they are faced with either expanding access and watching pharmaceutical costs rise dramatically, or restricting access and risking rising chronic disease and cost,” said Onitskansky. “Ilant’s model focuses on delivering real value with manageable treatment costs and clinically meaningful care that actually bends the cost curve.”
The company has direct contracting and transparent pricing through Eli Lilly’s Employer Connect program and is also working with Novo Nordisk – giving employers greater visibility into GLP-1 costs, one of the fastest-growing areas of healthcare spend.
